Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the ...

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

March 25 () - Merck said on Wednesday it would buy biotech Terns ‌Pharma in a deal valued ‌at up to $6.7 billion, as the ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...